



# BTVA<sup>®</sup>

## BRONCHOSCOPIC THERMAL VAPOR ABLATION

The InterVapor<sup>®</sup> System


### Uptake Medical<sup>®</sup>

A Broncus Company

Bronchoscopic  
Thermal Vapor  
Ablation (BTVA<sup>®</sup>)  
treatment included  
in the 2020 GOLD  
Guidelines


The **Uptake Medical InterVapor® System** is intended for treatment of patients with heterogeneous upper lobe emphysema to achieve bronchoscopic lung volume reduction by the application of heated water vapor to the most diseased lung segment(s) targeted for treatment.

The **InterVapor IP3® treatment plan** identifies the most diseased hyperinflated segments, and the dose of vapor to deliver, for optimal volume reduction.




The **InterVapor® System** is designed to reduce the volume and mass of the most diseased and hyperinflated segments of the lung, allowing the healthier segments to expand. This approach allows multiple treatments over time to maximize patient benefit.

Primary endpoint efficacy measures at 6 months and 12 months after vapour ablation<sup>(2)</sup>



### BTVA®:

- ✓ No risk of implant complications
- ✓ Vapor delivery time between 3 and 10 seconds
- ✓ Pneumothorax risk mitigated by gradual volume reduction
- ✓ Effective in CV+ and CV- patients<sup>(3)</sup>
- ✓ Compatible with 2.8mm working channel



### ORDERING INFORMATION

#### ORDER NUMBER UM-CTH-100 INCLUDES:

- InterVapor Catheter
- Personalized Procedure Program
- Drain Bag: UM-BAG-100

### CONTACT INFORMATION

info@uptakemedical.com or  
contact your local representative

[www.uptakemedical.com](http://www.uptakemedical.com)